個股熱度排行 | 2月14日港股收盤
根據uSMART輿情監測數據,14日港股交易時段,市場關注指數最高的5只股票是信達生物、舜宇光學科技、中國石油股份、歌禮制藥-B、融創中國。
2月14日—港股關注排行TOP5

信達生物

關注度第一爲信達生物,該股今日收盤下跌9.34%,報於28.65港元。近5個交易日累計下跌9.48%。在消息面和社交媒體方面,輿情以看空爲主。較被市場關注的消息有:
高盛維持信達生物“買入”評級 下調目標價28.8%至60.3港元
大摩下調信達生物目標價至65元 評級「增持」
舜宇光學科技

關注度第二爲舜宇光學科技,該股今日收盤上漲2.55%,報於192.80港元。近5個交易日累計下跌4.08%。在消息面和社交媒體方面,輿情以看多爲主。較被市場關注的消息有:
中金維持舜宇光學科技跑贏行業評級 目標價271.7港元
舜宇光學科技低開高走漲2.34% 中金維持跑贏行業評級
中國石油股份

關注度第三爲中國石油股份,該股今日收盤上漲2.66%,報於4.25港元。近5個交易日累計上漲3.66%。在消息面和社交媒體方面,輿情以看多爲主。較被市場關注的消息有:
恆生指數午盤收跌1.25%報24594點 中石油逆市漲3.14%
國際油價全線上漲 石油股應聲上行 中海油漲3.32%
歌禮制藥-B

關注度第四爲歌禮制藥-B,該股今日收盤上漲8.39%,報於4.52港元。近5個交易日累計上漲5.12%。在消息面和社交媒體方面,輿情以看多爲主。較被市場關注的消息有:
歌禮制藥-B漲超16% 其在歐洲多個國家遞交利託那韋上市許可申請
歌禮制藥漲逾14%重越20天線 於歐洲多國遞交利託那韋上市許可申請
融創中國

關注度第五爲融創中國,該股今日收盤下跌11.84%,報於9.68港元。近5個交易日累計下跌0.21%。在消息面和社交媒體方面,輿情以看空爲主。較被市場關注的消息有:
內房股午後跌幅擴大 融創中國跌超11%中國奧園跌超10%
穆迪下調融創評級至「B1」 展望降至負面
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.